CTAG2 Antibody (monoclonal) (M04)
Mouse monoclonal antibody raised against a partial recombinant CTAG2.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | O75638 |
Other Accession | NM_020994 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG2b Kappa |
Clone Names | 3H1 |
Calculated MW | 21090 Da |
Gene ID | 30848 |
---|---|
Other Names | Cancer/testis antigen 2, CT2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 62, CT62, L antigen family member 1, LAGE-1, CTAG2, ESO2, LAGE1 |
Target/Specificity | CTAG2 (NP_066274, 111 a.a. ~ 210 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | CTAG2 Antibody (monoclonal) (M04) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants.
References
Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. Wang XY, et al. Oncol Rep, 2009 Mar. PMID 19212631.Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Andrade VC, et al. Cancer Immun, 2008 Feb 1. PMID 18237105.Identification and expression analysis of novel LAGE-1 alleles with single nucleotide polymorphisms in cancer patients. Shao Y, et al. J Cancer Res Clin Oncol, 2008 Apr. PMID 17899192.A new specific gene expression in squamous cell carcinoma of the esophagus detected using representational difference analysis and cDNA microarray. Kan T, et al. Oncology, 2006. PMID 16446548.The LIFEdb database in 2006. Mehrle A, et al. Nucleic Acids Res, 2006 Jan 1. PMID 16381901.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.